Puma Biotechnology Liabilities 2024

Puma Biotechnology Aktienanalyse

What does Puma Biotechnology do?

Puma Biotechnology Inc. is a biopharmaceutical company based in Los Angeles. It was founded in 2010 and initially focused on the development of innovative cancer treatments. Since then, the company has significantly expanded and now offers a wide range of products and services all centered around cancer treatment. The company's business model revolves around developing drugs that address the need for novel and effective therapies to treat cancer. Puma Biotechnology Inc. is a leading player in this field and has already brought several successful products to market. One of the company's most well-known cancer treatments is Neratinib (also known as Nerlynx), which is used to treat breast cancer. Nerlynx received FDA approval in July 2017. Puma Biotechnology Inc. was founded in 2010 by Alan H. Auerbach, who had previously founded the biopharmaceutical company Cougar Biotechnology and successfully sold it to Johnson & Johnson. The history of Puma Biotechnology Inc. is marked by continuous growth. After its founding, the company acquired exclusive rights to develop neratinib for the treatment of breast cancer. The company has since conducted numerous studies and collected clinical data to prove the efficacy and safety of Nerlynx. After years of research, the medication finally received FDA approval in 2017. Puma Biotechnology Inc. has expanded its offerings since its founding and now offers a wide range of products and services centered around cancer treatment. One of the company's main areas of focus is research and development of cancer treatments. Puma Biotechnology Inc. continuously works on developing new drugs and therapies for a variety of cancer types, including breast cancer, lung cancer, and leukemia. The company is also involved in the production and marketing of pharmaceuticals. Neratinib is the company's most well-known product, but Puma Biotechnology Inc. has also brought other cancer treatments to the market. Additionally, Puma Biotechnology Inc. offers a wide range of services in the field of cancer treatment. The company is involved in the development of diagnostics and preventative measures and also offers training and consultations for doctors and patients. Nerlynx is Puma Biotechnology Inc.'s most well-known product and is now distributed worldwide. The medication is an oral therapeutic used for the adjuvant treatment of early-stage HER2-positive breast cancer in adults following adequate standard adjuvant therapy. It is taken by women who have already undergone chemotherapy, surgery, and radiation therapy. Neratinib works to prevent cancer recurrences by targeting the HER2 receptor, which normally promotes cancer cell growth. The medication blocks these receptors and can therefore inhibit tumor growth. In addition, Puma Biotechnology Inc. has also brought other products to the market, including Ribociclib, which is used in combination with other medications to treat ER-positive, HER2-negative breast cancer. In conclusion, Puma Biotechnology Inc. is a unique and emerging company with a focus on cancer treatments. Since its founding in 2010, the company has become a leading player in cancer combat. Puma Biotechnology Inc. is involved in the development of innovative therapeutic approaches, has achieved numerous medical successes, and brought many promising medications to the market. With Nerlynx, the company has introduced an effective medication for the treatment of breast cancer, and its potential is far from being realized. The company will undoubtedly play an important role in the treatment of cancer in the future. Puma Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Puma Biotechnology's Liabilities

Puma Biotechnology's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Puma Biotechnology's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Puma Biotechnology's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Puma Biotechnology's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Puma Biotechnology’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Puma Biotechnology stock

What is the level of liabilities of Puma Biotechnology this year?

Puma Biotechnology has a debt balance of 177.09 M USD this year.

What were the liabilities of Puma Biotechnology compared to the previous year?

The liabilities of Puma Biotechnology have increased by -11.68% dropped compared to the previous year.

What are the consequences of high debt for investors of Puma Biotechnology?

High liabilities can pose a risk for investors of Puma Biotechnology, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Puma Biotechnology?

Low liabilities mean that Puma Biotechnology has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Puma Biotechnology affect the company?

An increase in liabilities of Puma Biotechnology can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Puma Biotechnology affect the company?

A decrease in the liabilities of Puma Biotechnology can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Puma Biotechnology?

Some factors that can influence the liabilities of Puma Biotechnology include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Puma Biotechnology so important for investors?

The liabilities of Puma Biotechnology are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Puma Biotechnology take to modify the liabilities?

To change its liabilities, Puma Biotechnology can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Puma Biotechnology pay?

Over the past 12 months, Puma Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Puma Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of Puma Biotechnology?

The current dividend yield of Puma Biotechnology is .

When does Puma Biotechnology pay dividends?

Puma Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Puma Biotechnology?

Puma Biotechnology paid dividends every year for the past 0 years.

What is the dividend of Puma Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Puma Biotechnology located?

Puma Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Puma Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Puma Biotechnology from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Puma Biotechnology pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Puma Biotechnology in the year 2023?

In the year 2023, Puma Biotechnology distributed 0 USD as dividends.

In which currency does Puma Biotechnology pay out the dividend?

The dividends of Puma Biotechnology are distributed in USD.